BD and AlleCure link up on allergies tests:
This article was originally published in Clinica
Executive Summary
BD Biosciences, a division of Becton Dickinson, is to develop assays to support treatments for allergies and autoimmune diseases made by biopharmaceutical firm AlleCure. The two firms will jointly focus on developing laboratory tests for use with AlleCure's allergy vaccine technologies. The tests, which will be designed for research and clinical use, are expected to improve the identification of patients with specific allergies and to monitor how well the vaccines are working.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.